Efficacy and safety of fentanyl buccal for cancer pain management by administration through a soluble film: An update

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 303-306

  Delgado Guay, Marvin Omar ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer pain; Fentanyl buccal soluble film

Indexed keywords

ANTIVIRUS AGENT; CIMETIDINE; DEXAMETHASONE; FENTANYL; FENTANYL CITRATE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; MIDAZOLAM; MORPHINE; OMEPRAZOLE; ONDANSETRON; OPIATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; SCOPOLAMINE BUTYL BROMIDE; SERTRALINE; VALPROIC ACID;

ANALGESIA; CANCER PAIN; CANCER PATIENT; CHEEK MUCOSA; CONSTIPATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; ECONOMIC ASPECT; FILM COATING; FIRST PASS EFFECT; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFORMATION RETRIEVAL; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MUCOSAL ADMINISTRATION; NAUSEA; REVIEW; VOMITING;

EID: 79251477595     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMR.S7215     Document Type: Review

References (31)

1. Delgado-Guay MO, Bruera E. Management of pain in the older person with cancer. Part 1. Oncology. 2008; 22:56-61.
2. de Leon-Casasola OA. Current developments in opioid therapy for management of cancer pain. Clin J Pain. 2008; 24:S3-S7.
3. Yennurajalingam S, Braiteh F, Bruera E. Pain and terminal delirium research in the elderly. Clin Geriatr Med. 2005; 21:93-119.
4. Basso U, Monfardinin S. Multidimensional geriatric evaluation in elderly cancer patients: a practical approach. Eur J Cancer Care. 2004; 13:424-433.
5. Mercadante S, Arcuri E. Pharmacological management of cancer pain in the elderly. Drugs Aging. 2007; 24:761-776.
6. Dalal S, Del Fabbro E, Bruera E. Symptom control in palliative care - part 1: oncology as a paradigmatic example. J Palliat Med. 2006; 9: 391-408.
7. Aziz NM. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol. 2007; 46:417-443.
8. World Health Organization (WHO). Cancer Pain Relief and Palliative Care. Geneva, Switzerland: WHO, 1990:804.
9. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004; 18:177-183.
10. William L, Macleod R. Management of breakthrough pain in patients with cancer. Drugs. 2008; 68:913-924.
11. Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009; 20:1420-1433.
12. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2002; 41:661-680.
13. Prommer E. The role of Fentanyl in cancer-related pain. J Palliat Med. 2009; 12:947-954.
14. Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010; 21:1308-1314.
15. Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecal administered morphine, fentanyl, alfentanil, and sufentanyl. Anesthesiology. 2000; 92:739-753.
16. Dosen-Micovic L, Ivanovic M, Micovic V. Steric interactions and the activity of fentanyl analogs at the [mu]-opioid receptor. Bioorg Med Chem. 2006; 14:2887-2895.
17. Clarke RW, Ward RE. The role of 5-HT(1A)-receptors in fentanyl-induced bulbospinal inhibition of a spinal withdrawal reflex in the rabbit. Pain. 2000; 85:239-245.
18. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004; 28:497-504.
19. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother. 2007; 21:5-16.
20. Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology. 1999; 91:681-685.
21. Takane H, Nosaka A, Wakushima H, et al. Rifampin reduces the analgesic effect of transdermal fentanyl. Ann Pharmacother. 2005; 39: 2139-2140.
22. Webster LR. Fentanyl buccal tablets. Expert Opin Investig Drugs. 2006; 15:1469-1473.
23. Darwish M, Tempero K, Kirby M, Thompson J. Pharmacokinetic and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005; 44:1279-1286.
24. Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl for the management of pain. Drugs. 2010; 70:57-72.
25. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain. Cancer. 2009; 115:2571-2579.
26. Zeppetella G, Messina J, Xie F, Slatkin NE. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain. Pain Practice. 2010; 10:287-293.
27. Vasisht N, Gever LN, Tagarro I, Finn AL. Evaluation of the single-and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J Clin Pharmacol. 2010; 50:785-791.
28. Vasisht N, Gever LN, Tagarro I, Finn AL. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate. Clin Drug Investig. 2009; 29: 647-654.
29. Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 2010; 11:1017-1023.
30. Vasisht N, Stark J, Finn A. BEMA fentanyl shows a favorable pharma-cokinetic profle and dose linearity in healthy volunteers. Reg Anesth Pain Med. 2008; 32:8 2008 Annual General Meeting of the American Society of Anesthesiologists, October 17, 2008, Orlando FL.
31. Fentanyl buccal soluble film (Onsolis) for breakthrough cancer pain. The Medical Letter. 2010; 52:30-31.